June 2, 2025 12:39 PM EDT
R&D

Lyra’s stock soars on Phase 3 suc­cess for chron­ic rhi­nos­i­nusi­tis treat­ment

Ayisha Sharma

News Reporter

Lyra Ther­a­peu­tics’ shares shot up about 500% at mar­ket open on Mon­day af­ter the biotech said its nasal im­plant im­proved signs of an in­flam­ma­to­ry si­nus …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Pfiz­er ends Phase 2 tri­al for fi­nal Tril­li­um CD47 drug

Ad­vo­cates urge J&J to ‘put every­thing on the ta­ble’ for gene ther­a­py de­spite failed tri­al

Ex­clu­sive: Bob Langer-found­ed Syn­tis Bio gets $33M Se­ries A for obe­si­ty, rare dis­ease drugs

Beck­ley touts pos­i­tive mid-stage psy­che­del­ic da­ta fol­low­ing atai merg­er plans

Supreme Court pass­es on Ok­la­homa’s drug mid­dle­men spat

Ope­nAI-backed start­up re­leas­es new AI mod­els, claim­ing top per­for­mance in mak­ing an­ti­bod­ies

A service from the Financial Times